Evidence map›Paper›PMID 29152667›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2018

Correction to: Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis.

Sue Ping Thang, Mei Sim Lung, Grace Kong, Michael S Hofman, Jason Callahan, Michael Michael, Rodney J Hicks

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Sue Ping ThangCentre for Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Mei Sim LungDivision of Cancer Medicine, Neuroendocrine Tumour Unit, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Grace KongCentre for Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Michael S HofmanCentre for Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Jason CallahanCentre for Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Michael MichaelDivision of Cancer Medicine, Neuroendocrine Tumour Unit, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Rodney J HicksCentre for Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. Rod.Hicks@petermac.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

On page 4 of the original version of this article, the text "Eight (29%) of the patients had significant FDG-avid disease (i.e. with intensity above liver parenchyma) prior to treatment" needs to be corrected.

Identifiers

PMID29152667

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.